Study of AK117 with Azacitidine for High-Risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a new diagnosis of high-risk MDS.
- You are able to have bone marrow samples taken as part of the study.
- You have good enough veins for blood draws.
- You have not had treatment with certain similar drugs (CD47 or SIRPα blockers).
- You are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding bexmarilimab to standard azacitidine treatment helps people with higher-risk myelodysplastic syndromes (MDS), a type of blood cancer. It compares this combination to azacitidine plus a placebo to see which is more effective.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
This trial tests a new drug called AK117 combined with two standard treatments (azacitidine and venetoclax) for people with acute myeloid leukemia (AML). The goal is to see if this combination is safe and effective in treating the disease.
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.